Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s stock price rose 4.6% during mid-day trading on Wednesday . The stock traded as high as $15.20 and last traded at $15.10. Approximately 11,482 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 94,797 shares. The stock had previously closed at $14.43.
Rapport Therapeutics Trading Up 4.6 %
The business's 50 day moving average is $18.16 and its two-hundred day moving average is $20.66.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.07. On average, research analysts predict that Rapport Therapeutics will post -3.65 EPS for the current year.
Hedge Funds Weigh In On Rapport Therapeutics
A number of hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new stake in Rapport Therapeutics in the 2nd quarter worth about $380,000. Millennium Management LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter worth approximately $2,716,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Rapport Therapeutics during the second quarter worth approximately $1,757,000. Logos Global Management LP acquired a new stake in shares of Rapport Therapeutics during the second quarter worth approximately $4,859,000. Finally, SG Americas Securities LLC purchased a new position in Rapport Therapeutics during the third quarter valued at approximately $101,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
